Comparative effectiveness of BNT162b2 and ChAdOx1 nCoV-19 vaccines against COVID-19

BACKGROUND: Both BNT162b2 (Pfizer–BioNTech) and ChAdOx1 nCoV-19 (Oxford–AstraZeneca) vaccines have shown high efficacy against COVID-19 in randomized controlled trials. However, their comparative effectiveness against COVID-19 is unclear in the real world. We evaluated the comparative effectiveness...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Jie, Zhang, Weiya, Doherty, Michael, Wallace, Zachary S., Sparks, Jeffrey A., Lu, Na, Li, Xiaoxiao, Zeng, Chao, Lei, Guanghua, Zhang, Yuqing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9974059/
https://www.ncbi.nlm.nih.gov/pubmed/36855108
http://dx.doi.org/10.1186/s12916-023-02795-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9974059/
https://www.ncbi.nlm.nih.gov/pubmed/36855108
http://dx.doi.org/10.1186/s12916-023-02795-w

Ejemplares similares